Document Detail


In vitro simulation of thrombolysis inhibition.
MedLine Citation:
PMID:  18160584     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hyperfibrinolysis is a serious clinical complication. The inhibitory concentrations 50% of antifibrinolytics were analyzed in the microtiter plate clot lysis assay, using 50 microL of plasma clots, 10 microL of antifibrinolytic drug, 10 microL of 354 IU/mL (final) urokinase, 4.46 microg/mL (final) tissue-type plasminogen activator or 0.6 mg/mL plasmin, and 50 microL of pooled normal plasma as clot supernatant. The inhibitory concentrations 50% of lysine against urokinase or tissue-type plasminogen activator is 2.0 or 4.2 mM, against epsilon-amino-caproic acid 0.7 or 1.5 mM, against tranexamic acid 0.03 or 0.17 mM, respectively. The inhibitory concentrations 50% of lysine, epsilon-amino-caproic acid, or tranexamic acid against plasmin is 7.4, 0.4, or 0.04 mM. The inhibitory concentrations 50% of aprotinin against urokinase or tissue-type plasminogen activator is about 60 KIU/mL, against plasmin 19 KIU/mL. Lysine might be a new antifibrinolytic drug with a clinically interesting rapid pharmacokinetic. This data help correct dosing of antifibrinolytics to patients with hyperfibrinolysis.
Authors:
Thomas W Stief
Related Documents :
14595654 - Valproic acid increases smn levels in spinal muscular atrophy patient cells.
16364054 - In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteo...
20479544 - Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandron...
22095764 - The role of rna in mammalian prion protein conversion.
14751684 - Effect of iron limitation on the growth and cytotoxin production of salmonella cholerae...
9474814 - Identification of selenocysteine and selenomethionine in protein hydrolysates by high-p...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-12-26
Journal Detail:
Title:  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis     Volume:  14     ISSN:  1076-0296     ISO Abbreviation:  Clin. Appl. Thromb. Hemost.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-28     Completed Date:  2008-05-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508125     Medline TA:  Clin Appl Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  234-7     Citation Subset:  IM    
Affiliation:
Department of Clinical Chemistry, University Hospital, Marburg, Germany. thstief@med.uni
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
6-Aminocaproic Acid / pharmacology*
Antifibrinolytic Agents / pharmacology*
Aprotinin / pharmacology*
Humans
Lysine / pharmacology*
Tranexamic Acid / pharmacology*
Chemical
Reg. No./Substance:
0/Antifibrinolytic Agents; 1197-18-8/Tranexamic Acid; 56-87-1/Lysine; 60-32-2/6-Aminocaproic Acid; 9087-70-1/Aprotinin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for ...
Next Document:  In vitro simulation of extremely activated thrombolysis.